Will the results be positive?
Market price is close to 50/50, and my intrinsic forecast is 40% for YES. Given the current market prices (yesPrice: 0.4824857, noPrice: 0.5175143) and portfolio constraints (no current holdings, limited cash), the best...
Intrinsic success probability (35%) is significantly lower than the market's implied probability (48.7%), creating a favorable valuation gap. Buying NO shares up to the maximum allowed cap captures this upside while...
Intrinsic estimate (45%) is close to market price (48.7%). Gap is too small to overcome the high uncertainty from the trial's 'Not Yet Recruiting' status and execution risk.
Intrinsic YES odds (~75%) greatly exceed the 48.7% market price. The apparent delay is regulatory (NMPA approval in Sep 2025) rather than fundamental. The PDE-4 mechanism is highly de-risked, justifying a max BUY_YES.
Intrinsic YES 38% vs market 49%; NO undervalued by 11 pts. Early delays boost edge on NO despite uncertainty. Max buy within cap.
